<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240904081918&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;ff=20240904081918&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Wed, 04 Sep 2024 12:19:19 +0000</lastbuilddate>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Crotonylation of NAE1 Modulates Cardiac Hypertrophy via Gelsolin Neddylation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our findings provide new insights into the previously unrecognized role of crotonylation on nonhistone proteins during cardiac hypertrophy. We found that K238 crotonylation of NAE1 plays an essential role in mediating cardiac hypertrophy through GSN neddylation, which provides potential novel therapeutic targets for pathological hypertrophy and cardiac remodeling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 4. doi: 10.1161/CIRCRESAHA.124.324733. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac hypertrophy and its associated remodeling are among the leading causes of heart failure. Lysine crotonylation is a recently discovered posttranslational modification whose role in cardiac hypertrophy remains largely unknown. NAE1 (NEDD8-activating enzyme E1 regulatory subunit) is mainly involved in the neddylation modification of protein targets. However, the function of crotonylated NAE1 has not been defined. This study aims to elucidate the effects and mechanisms of NAE1 crotonylation on cardiac hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Crotonylation levels were detected in both human and mouse subjects with cardiac hypertrophy through immunoprecipitation and Western blot assays. TMT-labeled quantitative lysine crotonylome analysis was performed to identify the crotonylated proteins in a mouse cardiac hypertrophic model induced by transverse aortic constriction. We generated NAE1 knock-in mice carrying a crotonylation-defective lysine to arginine K238R (lysine to arginine mutation at site 238) mutation (NAE1 K238R) and NAE1 knock-in mice expressing a crotonylation-mimicking lysine to glutamine K238Q (lysine to glutamine mutation at site 238) mutation (NAE1 K238Q) to assess the functional role of crotonylation of NAE1 at K238 in pathological cardiac hypertrophy. Furthermore, we combined coimmunoprecipitation, mass spectrometry, and dot blot analysis that was followed by multiple molecular biological methodologies to identify the target GSN (gelsolin) and corresponding molecular events contributing to the function of NAE1 K238 crotonylation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The crotonylation level of NAE1 was increased in mice and patients with cardiac hypertrophy. Quantitative crotonylomics analysis revealed that K238 was the main crotonylation site of NAE1. Loss of K238 crotonylation in NAE1 K238R knock-in mice attenuated cardiac hypertrophy and restored the heart function, while hypercrotonylation mimic in NAE1 K238Q knock-in mice significantly enhanced transverse aortic constriction-induced pathological hypertrophic response, leading to impaired cardiac structure and function. The recombinant adenoviral vector carrying NAE1 K238R mutant attenuated, while the K238Q mutant aggravated Ang II (angiotensin II)-induced hypertrophy. Mechanistically, we identified GSN as a direct target of NAE1. K238 crotonylation of NAE1 promoted GSN neddylation and, thus, enhanced its protein stability and expression. NAE1 crotonylation-dependent increase of GSN promoted actin-severing activity, which resulted in adverse cytoskeletal remodeling and progression of pathological hypertrophy.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our findings provide new insights into the previously unrecognized role of crotonylation on nonhistone proteins during cardiac hypertrophy. We found that K238 crotonylation of NAE1 plays an essential role in mediating cardiac hypertrophy through GSN neddylation, which provides potential novel therapeutic targets for pathological hypertrophy and cardiac remodeling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39229723</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324733>10.1161/CIRCRESAHA.124.324733</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229723</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Jie Ju</dc:creator>
<dc:creator>Kai Wang</dc:creator>
<dc:creator>Fang Liu</dc:creator>
<dc:creator>Cui-Yun Liu</dc:creator>
<dc:creator>Yun-Hong Wang</dc:creator>
<dc:creator>Shao-Chong Wang</dc:creator>
<dc:creator>Lu-Yu Zhou</dc:creator>
<dc:creator>Xin-Min Li</dc:creator>
<dc:creator>Yu-Qin Wang</dc:creator>
<dc:creator>Xin-Zhe Chen</dc:creator>
<dc:creator>Rui-Feng Li</dc:creator>
<dc:creator>Shi-Jun Xu</dc:creator>
<dc:creator>Chen Chen</dc:creator>
<dc:creator>Mei-Hua Zhang</dc:creator>
<dc:creator>Su-Min Yang</dc:creator>
<dc:creator>Jin-Wei Tian</dc:creator>
<dc:creator>Kun Wang</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Crotonylation of NAE1 Modulates Cardiac Hypertrophy via Gelsolin Neddylation</dc:title>
<dc:identifier>pmid:39229723</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324733</dc:identifier>
</item>
<item>
<title>Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 4. doi: 10.1161/CIRCULATIONAHA.124.069903. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the ARTESiA trial (Apixaban for the Reduction of Thromboembolism in Patients With Device-Detected Subclinical Atrial Fibrillation), apixaban, compared with aspirin, reduced stroke or systemic embolism in patients with device-detected subclinical atrial fibrillation (SCAF). Clinical guidelines recommend considering SCAF episode duration when deciding whether to prescribe oral anticoagulation for this population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed a retrospective cohort study in ARTESiA. Using Cox regression adjusted for CHA<sub>2</sub>DS<sub>2</sub>-VASc score and treatment allocation (apixaban or aspirin), we assessed frequency of SCAF episodes and duration of the longest SCAF episode in the 6 months before randomization as predictors of stroke risk and of apixaban treatment effect.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 3986 patients with complete baseline SCAF data, 703 (17.6%) had no SCAF episode ≥6 minutes in the 6 months before enrollment. Among 3283 patients (82.4%) with ≥1 episode of SCAF ≥6 minutes in the 6 months before enrollment, 2542 (77.4%) had up to 5 episodes, and 741 (22.6%) had ≥6 episodes. The longest episode lasted &lt;1 hour in 1030 patients (31.4%), 1 to &lt;6 hours in 1421 patients (43.3%), and >;6 hours in 832 patients (25.3%). Higher baseline SCAF frequency was not associated with increased risk of stroke or systemic embolism: 1.1% for 1 to 5 episodes versus 1.2%/patient-year for ≥6 episodes (adjusted hazard ratio, 0.89 [95% CI, 0.59-1.34]). In an exploratory analysis, patients with previous SCAF but no episode ≥6 minutes in the 6 months before enrollment had a lower risk of stroke or systemic embolism than patients with at least one episode during that period (0.5% versus 1.1%/patient-year; adjusted hazard ratio, 0.48 [95% CI, 0.27-0.85]). The frequency of SCAF did not modify the reduction in stroke or systemic embolism with apixaban (<i>P</i><sub>interaction</sub>=0.1). The duration of the longest SCAF episode in the 6 months before enrollment was not associated with the risk of stroke or systemic embolism during follow-up (&lt;1 hour: 1.0%/patient-year [reference]; 1-6 hours: 1.2%/patient-year [adjusted hazard ratio, 1.27 (95% CI, 0.85-1.90)]; >;6 hours: 1.0%/patient-year [adjusted hazard ratio, 1.02 (95% CI, 0.63-1.66)]). SCAF duration did not modify the reduction in stroke or systemic embolism with apixaban (<i>P</i><sub>trend</sub>=0.1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In ARTESiA, baseline SCAF frequency and longest episode duration were not associated with risk of stroke or systemic embolism and did not modify the effect of apixaban on reduction of stroke or systemic embolism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01938248.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39229707</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069903>10.1161/CIRCULATIONAHA.124.069903</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229707</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>William F McIntyre</dc:creator>
<dc:creator>Alexander P Benz</dc:creator>
<dc:creator>Jeff S Healey</dc:creator>
<dc:creator>Stuart J Connolly</dc:creator>
<dc:creator>Mu Yang</dc:creator>
<dc:creator>Shun Fu Lee</dc:creator>
<dc:creator>Thalia S Field</dc:creator>
<dc:creator>Marco Alings</dc:creator>
<dc:creator>J Benezet-Mazuecos</dc:creator>
<dc:creator>Giuseppe Boriani</dc:creator>
<dc:creator>J Cosedis Nielsen</dc:creator>
<dc:creator>Michael R Gold</dc:creator>
<dc:creator>Francesco Pergolini</dc:creator>
<dc:creator>Taya V Glotzer</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Risk of Stroke or Systemic Embolism According to Baseline Frequency and Duration of Subclinical Atrial Fibrillation: Insights From the ARTESiA Trial</dc:title>
<dc:identifier>pmid:39229707</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069903</dc:identifier>
</item>
<item>
<title>Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229700/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this trial of Chinese patients with uncontrolled hypertension on a standardized triple pharmacotherapy, RDN was safe and reduced ambulatory and office BP at 6 months compared with sham.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 4. doi: 10.1161/CIRCULATIONAHA.124.069215. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Renal denervation (RDN) can lower blood pressure (BP) in patients with hypertension in both the presence and absence of medication. This is the first sham-controlled trial investigating the safety and efficacy of RDN in China.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This prospective, multicenter, randomized, patient- and outcome-assessor-blinded, sham-controlled trial investigated radiofrequency RDN in patients with hypertension on standardized triple antihypertensive therapy. Eligible patients were randomized 1:1 to undergo RDN using a multi-electrode radiofrequency catheter (Iberis; AngioCare, Shanghai, China) or a sham procedure. The primary efficacy outcome was the between-group difference in baseline-adjusted change in mean 24-hour ambulatory systolic BP from randomization to 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 217 randomized patients (mean age, 45.3±10.2 years; 21% female), 107 were randomized to RDN and 110 were randomized to sham control. At 6 months, there was a greater reduction in 24-hour systolic BP in the RDN (-13.0±12.1 mm Hg) compared with the sham control group (-3.0±13.0 mm Hg; baseline-adjusted between-group difference, -9.4 mm Hg [95% CI, -12.8 to -5.9]; <i>P</i>&lt;0.001). Compared with sham, 24-hour diastolic BP was lowered by -5.0 mm Hg ([95% CI, -7.5 to -2.4]; <i>P</i>&lt;0.001) 6 months after RDN, and office systolic and diastolic BP was lowered by -6.4 mm Hg ([95% CI, -10.5 to -2.3]; <i>P</i>=0.003) and -5.1 mm Hg ([95% CI, -8.2 to -2.0]; <i>P</i>=0.001), respectively. One patient in the RDN group experienced an access site complication (hematoma), which resolved without sequelae. No other major device- or procedure-related safety events occurred through follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this trial of Chinese patients with uncontrolled hypertension on a standardized triple pharmacotherapy, RDN was safe and reduced ambulatory and office BP at 6 months compared with sham.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://clinicaltrials.gov; Unique identifier: NCT02901704.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229700/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39229700</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069215>10.1161/CIRCULATIONAHA.124.069215</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229700</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiongjing Jiang</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:creator>Hui Dong</dc:creator>
<dc:creator>Jing Yu</dc:creator>
<dc:creator>Shuhua Yu</dc:creator>
<dc:creator>Xiaoping Chen</dc:creator>
<dc:creator>Peijian Wang</dc:creator>
<dc:creator>Zhiqiang Li</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Zhifang Wang</dc:creator>
<dc:creator>Zheng Ji</dc:creator>
<dc:creator>Yifei Dong</dc:creator>
<dc:creator>Bing Han</dc:creator>
<dc:creator>Zhiming Zhu</dc:creator>
<dc:creator>Yulin Chen</dc:creator>
<dc:creator>Jianzhong Xu</dc:creator>
<dc:creator>Xingsheng Zhao</dc:creator>
<dc:creator>Weidong Fan</dc:creator>
<dc:creator>Wen Xie</dc:creator>
<dc:creator>Brad Hubbard</dc:creator>
<dc:creator>Xi Hu</dc:creator>
<dc:creator>Kazuomi Kario</dc:creator>
<dc:creator>Runlin Gao</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Chinese Patients With Uncontrolled Hypertension: The Randomized, Sham-Controlled, Multi-Center Iberis-HTN Trial</dc:title>
<dc:identifier>pmid:39229700</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069215</dc:identifier>
</item>
<item>
<title>Sinus sequestration due to transcatheter heart valve endothelialization after transcatheter aortic valve replacement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39229672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae606. doi: 10.1093/eurheartj/ehae606. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39229672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39229672</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae606>10.1093/eurheartj/ehae606</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39229672</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Masatoshi Sato</dc:creator>
<dc:creator>Nobuhiro Yoshijima</dc:creator>
<dc:creator>Fumiaki Yashima</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Sinus sequestration due to transcatheter heart valve endothelialization after transcatheter aortic valve replacement</dc:title>
<dc:identifier>pmid:39229672</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae606</dc:identifier>
</item>
<item>
<title>Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Maternal CVD was associated with an increased risk of CVD in offspring during childhood and young adulthood. Paternal comparison suggests that genetic or shared familial factors may not fully explain this association.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae547. doi: 10.1093/eurheartj/ehae547. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: A variety of maternal heart conditions are associated with abnormal placentation and reduced foetal growth. However, their impact on offspring's long-term cardiovascular health is poorly studied. This study aims to investigate the association between intrauterine exposure to pre-existing maternal cardiovascular disease (CVD) and offspring CVD occurring from infancy to early adulthood, using paternal CVD as a negative control.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This nationwide cohort study used register data of live singletons without major malformations or congenital heart disease born between 1992 and 2019 in Sweden. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusted for essential maternal characteristics. Paternal CVD served as a negative control for assessment of unmeasured genetic and environmental confounding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of the 2 597 786 offspring analysed (49.1% female), 26 471 (1.0%) were born to mothers with pre-existing CVD. During a median follow-up of 14 years (range 1-29 years), 17 382 offspring were diagnosed with CVD. Offspring of mothers with CVD had 2.09 times higher adjusted HR of CVD (95% CI 1.83, 2.39) compared with offspring of mothers without CVD. Compared with maternal CVD, paternal CVD showed an association of smaller magnitude (HR 1.49, 95% CI 1.32, 1.68). Increased hazards of offspring CVD were also found when stratifying maternal CVD into maternal arrhythmia (HR 2.94, 95% CI 2.41, 3.58), vascular (HR 1.59, 95% CI 1.21, 2.10), and structural heart diseases (HR 1.48, 95% CI 1.08, 2.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Maternal CVD was associated with an increased risk of CVD in offspring during childhood and young adulthood. Paternal comparison suggests that genetic or shared familial factors may not fully explain this association.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228375/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39228375</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae547>10.1093/eurheartj/ehae547</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228375</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Muhammad Zakir Hossin</dc:creator>
<dc:creator>Kalliopi Kazamia</dc:creator>
<dc:creator>Jonas Faxén</dc:creator>
<dc:creator>André Rudolph</dc:creator>
<dc:creator>Kari Johansson</dc:creator>
<dc:creator>Anna Sandström</dc:creator>
<dc:creator>Neda Razaz</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood</dc:title>
<dc:identifier>pmid:39228375</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae547</dc:identifier>
</item>
<item>
<title>Vulnerable plaque and major adverse cardiovascular events: anatomy of a failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228369/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae553. doi: 10.1093/eurheartj/ehae553. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228369/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39228369</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae553>10.1093/eurheartj/ehae553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228369</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Vulnerable plaque and major adverse cardiovascular events: anatomy of a failure</dc:title>
<dc:identifier>pmid:39228369</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae553</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228366/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae567. doi: 10.1093/eurheartj/ehae567. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228366/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39228366</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae567>10.1093/eurheartj/ehae567</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228366</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: SELECT renoprotective effects of semaglutide in non-diabetic, obese patients with cardiovascular disease</dc:title>
<dc:identifier>pmid:39228366</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae567</dc:identifier>
</item>
<item>
<title>Late gadolinium enhancement and anomalous coronary aortic origin in a large paediatric cohort</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228280/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae545. doi: 10.1093/eurheartj/ehae545. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228280/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39228280</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae545>10.1093/eurheartj/ehae545</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228280</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shagun Sachdeva</dc:creator>
<dc:creator>Lauren Ferrino</dc:creator>
<dc:creator>Tam T Doan</dc:creator>
<dc:creator>Dana Reaves-O'Neal</dc:creator>
<dc:creator>Stephen Dolgner</dc:creator>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Massimo A Padalino</dc:creator>
<dc:creator>Domenico Corrado</dc:creator>
<dc:creator>Prakash Masand</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Late gadolinium enhancement and anomalous coronary aortic origin in a large paediatric cohort</dc:title>
<dc:identifier>pmid:39228280</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae545</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39228278/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 4:ehae531. doi: 10.1093/eurheartj/ehae531. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39228278/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39228278</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae531>10.1093/eurheartj/ehae531</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39228278</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:creator>Massimo Volpe</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk</dc:title>
<dc:identifier>pmid:39228278</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae531</dc:identifier>
</item>
<item>
<title>Finding the right needle in the haystack: the real challenge of AF screening</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39227000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 21:S0735-1097(24)08247-0. doi: 10.1016/j.jacc.2024.08.036. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39227000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39227000</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.036>10.1016/j.jacc.2024.08.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39227000</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Xiaoxi Yao</dc:creator>
<dc:creator>Peter A Noseworthy</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Finding the right needle in the haystack: the real challenge of AF screening</dc:title>
<dc:identifier>pmid:39227000</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.036</dc:identifier>
</item>
<item>
<title>Unveiling the Unseen: Myosin Inhibitors Cause Reverse Remodeling of Left Ventricular Macro and Microstructure by CMR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226999/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08252-4. doi: 10.1016/j.jacc.2024.08.040. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226999/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226999</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.040>10.1016/j.jacc.2024.08.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226999</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlos E Rochitte</dc:creator>
<dc:creator>Clerio F Azevedo</dc:creator>
<dc:creator>Fabio Fernandes</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unveiling the Unseen: Myosin Inhibitors Cause Reverse Remodeling of Left Ventricular Macro and Microstructure by CMR</dc:title>
<dc:identifier>pmid:39226999</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.040</dc:identifier>
</item>
<item>
<title>Trusting the True Experts Through Patient-Reported Health Status in Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226998/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08274-3. doi: 10.1016/j.jacc.2024.08.043. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226998/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226998</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.043>10.1016/j.jacc.2024.08.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226998</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Nosheen Reza</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Trusting the True Experts Through Patient-Reported Health Status in Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:39226998</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.043</dc:identifier>
</item>
<item>
<title>The Case for Restoring Organelles to Treat Ischemic Cardiomyopathy: Is DEPP1 an Attractive Target?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226384/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):787-790. doi: 10.1161/CIRCULATIONAHA.124.070750. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226384/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226384</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070750>10.1161/CIRCULATIONAHA.124.070750</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226384</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Abhinav Diwan</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Case for Restoring Organelles to Treat Ischemic Cardiomyopathy: Is DEPP1 an Attractive Target?</dc:title>
<dc:identifier>pmid:39226384</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070750</dc:identifier>
</item>
<item>
<title>Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):e226-e227. doi: 10.1161/CIRCULATIONAHA.124.069707. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226383</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069707>10.1161/CIRCULATIONAHA.124.069707</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226383</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mikhail N Kosiborod</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Kosiborod et al to Letter Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial"</dc:title>
<dc:identifier>pmid:39226383</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069707</dc:identifier>
</item>
<item>
<title>Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):816-820. doi: 10.1161/CIRCULATIONAHA.122.061322. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226382</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061322>10.1161/CIRCULATIONAHA.122.061322</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226382</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yvo Flores</dc:creator>
<dc:creator>Gerald Zapata-Torres</dc:creator>
<dc:creator>Agustín Nuñez</dc:creator>
<dc:creator>Douglas J Matthies</dc:creator>
<dc:creator>Larissa Alemán</dc:creator>
<dc:creator>Carolina Hernández-Fuentes</dc:creator>
<dc:creator>Gina Sánchez</dc:creator>
<dc:creator>Eyleen Araya</dc:creator>
<dc:creator>Fanny Guzman</dc:creator>
<dc:creator>Zully Pedrozo</dc:creator>
<dc:creator>Salvador Guardiola</dc:creator>
<dc:creator>Mónica Varese</dc:creator>
<dc:creator>Ernest Giralt</dc:creator>
<dc:creator>Ivan Maslov</dc:creator>
<dc:creator>Mark Del Borgo</dc:creator>
<dc:creator>Robert E Widdop</dc:creator>
<dc:creator>Silvana Valdebenito</dc:creator>
<dc:creator>Eliseo A Eugenin</dc:creator>
<dc:creator>Mario Chiong</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>María Paz Ocaranza</dc:creator>
<dc:creator>Marcelo J Kogan</dc:creator>
<dc:creator>Sergio Lavandero</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Angiotensin-(1-9) Retro-Enantiomer Peptide With Cardioprotective Activity</dc:title>
<dc:identifier>pmid:39226382</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.061322</dc:identifier>
</item>
<item>
<title>Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226381/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>Guidelines help to facilitate treatment decisions based on available evidence, and also to provide recommendations in areas of uncertainty. In this paper, we compare the recommendations for stroke workup and secondary prevention of ischemic stroke and transient ischemic attack of the American Heart Association (AHA)/American Stroke Association (ASA) with the European Stroke Organization (ESO) guidelines. The primary aim of this paper is to offer clinicians guidance by identifying areas where...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):806-815. doi: 10.1161/CIRCULATIONAHA.124.069651. Epub 2024 Sep 3.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Guidelines help to facilitate treatment decisions based on available evidence, and also to provide recommendations in areas of uncertainty. In this paper, we compare the recommendations for stroke workup and secondary prevention of ischemic stroke and transient ischemic attack of the American Heart Association (AHA)/American Stroke Association (ASA) with the European Stroke Organization (ESO) guidelines. The primary aim of this paper is to offer clinicians guidance by identifying areas where there is consensus and where consensus is lacking, in the absence or presence of high-level evidence. We compared AHA/ASA with the ESO guideline recommendations for 7 different topics related to diagnostic stroke workup and secondary prevention. We categorized the recommendations based on class and level of evidence to determine whether there were relevant differences in the ratings of evidence that the guidelines used for its recommendations. Finally, we summarized major topics of agreement and disagreement, while also prominent knowledge gaps were identified. In total, we found 63 ESO and 82 AHA/ASA recommendations, of which 38 were on the same subject. Most recommendations are largely similar, but not all are based on high-level evidence. For many recommendations, AHA/ASA and ESO assigned different levels of evidence. For the 10 recommendations with <i>Level A</i> evidence (high quality) in AHA/ASA, ESO only labeled 4 of these as <i>high quality</i>. There are many remaining issues with either no or insufficient evidence, and some topics that are not covered by both guidelines. Most ESO and AHA/ASA Guideline recommendations for stroke workup and secondary prevention were similar. However not all were based on high-level evidence and the appointed level of evidence often differed. Clinicians should not blindly follow all guideline recommendations; the accompanying level of evidence informs which recommendations are based on robust evidence. Topics with lower levels of evidence, or those with recommendations that disagree or are missing, may be an incentive for further clinical research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226381/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226381</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069651>10.1161/CIRCULATIONAHA.124.069651</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226381</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Maxim J H L Mulder</dc:creator>
<dc:creator>Tim Y Cras</dc:creator>
<dc:creator>James Shay</dc:creator>
<dc:creator>Diederik W J Dippel</dc:creator>
<dc:creator>James F Burke</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Comparison of American and European Guideline Recommendations for Diagnostic Workup and Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack</dc:title>
<dc:identifier>pmid:39226381</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069651</dc:identifier>
</item>
<item>
<title>Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226380/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):e224-e225. doi: 10.1161/CIRCULATIONAHA.123.067970. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226380/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226380</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067970>10.1161/CIRCULATIONAHA.123.067970</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226380</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Robin A P Weir</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Weir Regarding Article, "Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity"</dc:title>
<dc:identifier>pmid:39226380</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067970</dc:identifier>
</item>
<item>
<title>Using Behavioral Science to Improve Cardiovascular Health</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39226379/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 3;150(10):743-745. doi: 10.1161/CIRCULATIONAHA.124.070103. Epub 2024 Sep 3.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39226379/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39226379</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070103>10.1161/CIRCULATIONAHA.124.070103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39226379</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Using Behavioral Science to Improve Cardiovascular Health</dc:title>
<dc:identifier>pmid:39226379</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070103</dc:identifier>
</item>
<item>
<title>Monocytes Reprogrammed by 4-PBA Potently Contribute to the Resolution of Inflammation and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39224974/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study describes a robust and effective approach to generate resolving monocytes, characterizes novel mechanisms for targeted monocyte reprogramming, and offers a precision therapeutics for atherosclerosis based on delivering reprogrammed resolving monocytes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 3. doi: 10.1161/CIRCRESAHA.124.325023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronic inflammation initiated by inflammatory monocytes underlies the pathogenesis of atherosclerosis. However, approaches that can effectively resolve chronic low-grade inflammation targeting monocytes are not readily available. The small chemical compound 4-phenylbutyric acid (4-PBA) exhibits broad anti-inflammatory effects in reducing atherosclerosis. Selective delivery of 4-PBA reprogrammed monocytes may hold novel potential in providing targeted and precision therapeutics for the treatment of atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Systems analyses integrating single-cell RNA sequencing and complementary immunologic approaches characterized key resolving characteristics as well as defining markers of reprogrammed monocytes trained by 4-PBA. Molecular mechanisms responsible for monocyte reprogramming were assessed by integrated biochemical and genetic approaches. The intercellular propagation of homeostasis resolution was evaluated by coculture assays with donor monocytes trained by 4-PBA and recipient naive monocytes. The in vivo effects of monocyte resolution and atherosclerosis prevention by 4-PBA were assessed with the high-fat diet-fed <i>ApoE</i><sup><i>-/-</i></sup> mouse model with IP 4-PBA administration. Furthermore, the selective efficacy of 4-PBA-trained monocytes was examined by IV transfusion of ex vivo trained monocytes by 4-PBA into recipient high-fat diet-fed <i>ApoE</i><sup><i>-/-</i></sup> mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: In this study, we found that monocytes can be potently reprogrammed by 4-PBA into an immune-resolving state characterized by reduced adhesion and enhanced expression of anti-inflammatory mediator CD24. Mechanistically, 4-PBA reduced the expression of ICAM-1 (intercellular adhesion molecule 1) via reducing peroxisome stress and attenuating SYK (spleen tyrosine kinase)-mTOR (mammalian target of rapamycin) signaling. Concurrently, 4-PBA enhanced the expression of resolving mediator CD24 through promoting PPARγ (peroxisome proliferator-activated receptor γ) neddylation mediated by TOLLIP (toll-interacting protein). 4-PBA-trained monocytes can effectively propagate anti-inflammation activity to neighboring monocytes through CD24. Our data further demonstrated that 4-PBA-trained monocytes effectively reduce atherosclerosis pathogenesis when administered in vivo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study describes a robust and effective approach to generate resolving monocytes, characterizes novel mechanisms for targeted monocyte reprogramming, and offers a precision therapeutics for atherosclerosis based on delivering reprogrammed resolving monocytes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39224974/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39224974</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325023>10.1161/CIRCRESAHA.124.325023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39224974</guid>
<pubDate>Tue, 03 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Shuo Geng</dc:creator>
<dc:creator>Ran Lu</dc:creator>
<dc:creator>Yao Zhang</dc:creator>
<dc:creator>Yajun Wu</dc:creator>
<dc:creator>Ling Xie</dc:creator>
<dc:creator>Blake Caldwell</dc:creator>
<dc:creator>Kisha Pradhan</dc:creator>
<dc:creator>Ziyue Yi</dc:creator>
<dc:creator>Jacqueline Hou</dc:creator>
<dc:creator>Feng Xu</dc:creator>
<dc:creator>Xian Chen</dc:creator>
<dc:creator>Liwu Li</dc:creator>
<dc:date>2024-09-03</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Monocytes Reprogrammed by 4-PBA Potently Contribute to the Resolution of Inflammation and Atherosclerosis</dc:title>
<dc:identifier>pmid:39224974</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325023</dc:identifier>
</item>
<item>
<title>Management of Antiplatelet Therapy After Coronary Stenting in Patients Requiring Non-Cardiac Surgery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222897/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 22:S0735-1097(24)08251-2. doi: 10.1016/j.jacc.2024.08.039. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222897/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39222897</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.039>10.1016/j.jacc.2024.08.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222897</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Management of Antiplatelet Therapy After Coronary Stenting in Patients Requiring Non-Cardiac Surgery</dc:title>
<dc:identifier>pmid:39222897</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.039</dc:identifier>
</item>
<item>
<title>Impact of Renal &amp;amp; Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39222896/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240904081918&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Baseline end-organ function were associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and Control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 23:S0735-1097(24)08275-5. doi: 10.1016/j.jacc.2024.08.044. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: TRILUMINATE Pivotal is a prospective, randomized, controlled study of patients with severe tricuspid regurgitation (TR). Venous congestion due to TR may lead to end-organ dysfunction and failure. The potential to reverse or stop further deterioration in end-organ function is an important goal of treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: Examine changes in end-organ function after tricuspid transcatheter edge-to-edge repair (TEER) and assess the association of baseline end-organ function with heart failure (HF) hospitalizations and mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Subjects were randomized 1:1 to either the TEER group (TriClip™ System + medical therapy) or Control group (medical therapy alone). Laboratory assessments and TR grading were performed at baseline and at all follow-up visits (discharge, 30 days, 6 months, and 12 months). An independent echocardiography core laboratory assessed TR severity and an independent clinical events committee adjudicated adverse events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 572 subjects were enrolled and randomized (285 TEER, 287 Control). Patients with moderate to severe end-organ impairment (eGFR &lt;45 ml/min/1.73m<sup>2</sup> or MELD-XI >;15) at baseline had increased incidence of HF hospitalization and death through 12 months, regardless of treatment. There were no statistically significant differences between TEER and Control in eGFR or MELD-XI at 12 months. In subgroup analyses examining only successful TEER patients (moderate or less TR at discharge) compared to control patients, as well as when censoring patients with normal baseline values, both eGFR (+3.55 ± 1.04 vs 0.07 ± 1.10 , p=0.022) and MELD-XI (-0.52 ± 0.18 vs 0.34 ± 0.18, p=0.0007) improved.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Baseline end-organ function were associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and Control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically meaningful and reduce HF hospitalization or death.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39222896/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240904081918&v=2.18.0.post9+e462414">39222896</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.044>10.1016/j.jacc.2024.08.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39222896</guid>
<pubDate>Mon, 02 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ulrich P Jorde</dc:creator>
<dc:creator>Raymond Benza</dc:creator>
<dc:creator>Patrick M McCarthy</dc:creator>
<dc:creator>Gorav Ailawadi</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Peter Tadros</dc:creator>
<dc:creator>Hursh Naik</dc:creator>
<dc:creator>Neil Fam</dc:creator>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Sandhya Murthy</dc:creator>
<dc:creator>Saibal Kar</dc:creator>
<dc:creator>Ralph Stephan von Bardeleben</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Nadira Hamid</dc:creator>
<dc:creator>Jacob Zbinden</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>David Adams</dc:creator>
<dc:date>2024-09-02</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Impact of Renal &amp;amp; Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair</dc:title>
<dc:identifier>pmid:39222896</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.044</dc:identifier>
</item>





























</channel>
</rss>